DXSE:F:F-Xtrackers Stoxx Europe 600 Health Care Swap UCITS ETF 1C (EUR)

ETF | Others |

Last Closing

USD 252.35

Change

+1.05 (+0.42)%

Market Cap

N/A

Volume

163.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.11 (-0.41%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.27 (-0.54%)

USD 108.20B
SXR8:F iShares Core S&P 500 UCITS ETF..

+1.02 (+0.19%)

USD 93.32B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.29 (-0.52%)

USD 86.92B
SXRZ:F iShares VII PLC - iShares Nikk..

-1.50 (-0.64%)

USD 53.24B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.48 (+0.50%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.12 (-0.77%)

USD 51.19B
XJSE:F Xtrackers II - Japan Governmen..

+0.08 (+0.96%)

USD 41.09B
0ZC:F Zscaler Inc

+5.84 (+4.01%)

USD 37.92B

ETFs Containing DXSE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.43% 93% A 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.43% 90% A- 73% C
Trailing 12 Months  
Capital Gain 25.89% 84% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.89% 81% B- 68% D+
Trailing 5 Years  
Capital Gain 70.76% 84% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.76% 84% B 64% D
Average Annual (5 Year Horizon)  
Capital Gain 8.75% 71% C- 68% D+
Dividend Return 8.75% 69% C- 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.45% 71% C- 91% A-
Risk Adjusted Return 103.55% 98% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike